MapLight Therapeutics, Inc. - 8-K Filing

MapLight Therapeutics reports Q3 2026 net loss of $51.6 million and announces $463.4 million cash position expected to fund operations through 2028. (Items: 2.02 Results of Operations and Financial Condition, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $MPLT

Read the full article at SEC EDGAR

More Regulatory news